Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

New Horizon Health 1H21: On Track to a Strong Year

New Horizon Health (诺辉健康) IPO Trading: Supply-Demand Imbalance

New Horizon Health (诺辉健康) IPO: Room to Fly

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Bottom-Up

<ul>
<li>New Horizon Health reported a solid set of preliminary results for 1H2023</li>
<li>We speak to the company's management post result announcement to figure out the key drivers and summarize the key points in this note.</li>
<li>The company upgraded its full year guidance and is on track to meet its long term target.</li>
</ul>


New Horizon Health reported a solid set of preliminary results for 1H2023
We speak to the company's management post result announcement to figure out the key drivers and summarize the key points in this note.
The company upgraded its full year guidance and is on track to meet its long term target.


New Horizon Health 1H23: Management Call Takeaway